| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Regulation FD Disclosure
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requ... |
| 16 Oct 2026 |
8-K: Other Events
On October 16, 2026, the board of directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and set October 28, 2... |
| 05 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression |
| 16 Sep 2026 |
8-K: Other Events
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors a... |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET |
| 07 Aug 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination ... |
| 22 Jul 2026 |
8-K: Other Events
In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that ... |
| 04 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
NRx Pharmaceutics, Inc., a Delaware corporation (the “Company”) proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter prov... |
| 02 Jun 2026 |
8-K: Other Events
WILMINGTON, Del., June 2, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its comm... |
| 24 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No. 1 (this “Amendment”) to the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended (the “Plan”) was adopted by the Board of Directors (“Board”) of NRx Pharmaceuticals, Inc., a Delaware corporation (the “Comp... |
| 17 Feb 2026 |
8-K: Other Events
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting. |
| 17 Feb 2026 |
8-K: Other Events
We have acted as counsel for NRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with (a) the Company’s filing on the date hereof with the Securities and Exchange Commission (the “Commission”) pursuant to Rul... |
| 02 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 27, 2026, the Board of Directors of the Company appointed Joseph M. Casper, age 75, as the Chief Operating Officer of the Company, effective January 27, 2026. |
| 16 Jan 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure +1 more
WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Ann... |
| 29 Dec 2025 |
8-K: Regulation FD Disclosure
Re: Debt Cancellation Agreement/ Pay-Off Letter (the “Letter”). |
| 26 Nov 2025 |
8-K: Changes in Registrant's Certifying Accountant
We were previously the independent registered public accounting firm for NRX Pharmaceuticals, Inc. and under the date of March 14, 2025, we reported on the consolidated financial statements of NRX Pharmaceuticals, Inc. and Subsidiaries, ... |
| 23 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director |
| 26 Sep 2025 |
8-K: Other Events
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s |
| 12 Sep 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida Peninsula. |
Loading...